Evercore ISI raised the firm’s price target on West Pharmaceutical (WST) to $350 from $275 and keeps an Outperform rating on the shares following quarterly results. The firm says the company is delivering across the board amid a choppy macro environment, and setting the table for a strong second half of the year and 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical rises 23.9%
- Early notable gainers among liquid option names on July 24th
- Strong Performance and Promising Outlook: West Pharmaceutical Services Receives Buy Rating from Matt Larew
- West Pharmaceutical Services Reports Strong Q2 2025 Results
- West Pharmaceutical ups FY25 adjusted EPS view to $6.65-$6.85 from $6.15-$6.35